Meeting
2023 ASCO Annual Meeting
Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.
Authors
Heather Derry-Vick
Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ
Heather Derry-Vick , Jacob Peter Zaemes , Jaeil Ahn , Lauren Pascual , Brittany Sinclaire , Shaked Lev-Ari , Adil Alaoui , Aishwarya Sridhar , David Adams , Alexandra Della Pia , Andrew L Pecora , Michael B. Atkins , Andrew Ip , Neil J. Shah
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Psychosocial and Communication Research
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 12134)
DOI
10.1200/JCO.2023.41.16_suppl.12134
Abstract #
12134
Poster Bd #
502
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.
First Author: Karim Amrane Sr.
Poster
2023 ASCO Annual Meeting
Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).
First Author: Katharine Andress Rowe Price
Poster
2023 ASCO Annual Meeting
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.
First Author: Nan Chen